Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2020
Tenax Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
(CommissionFile Number)
(IRS EmployerIdentification No.)
ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⬜ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⬜ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⬜ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⬜ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company               
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⬜

Item 8.01      
Other Items.
On June 2, 2020, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing that on May 29, 2020 the Company received top line data results on its Phase 2 clinical study of levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).
The Company also held a webcast call on June 2, 2020 to review the results. A copy of the press release is attached hereto as Exhibit 99.1 and the presentation materials for the webcast call is attached hereto as Exhibit 99.2, both of which are incorporated herein by reference.
Item 9.01 
Financial Statements and Exhibits.
Exhibit No.
Press Release dated June 2, 2020.
Presentation materials dated June 2, 2020.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 2, 2020
Tenax Therapeutics, Inc.
By: /s/ Michael B. Jebsen
Michael B. Jebsen
President and Chief Financial Officer

Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Tenax Therapeutics Charts.
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Tenax Therapeutics Charts.